Hello List,
Clifton Mining (CFTN-OTC) and American Biotech produce a colloidal silver
compound that arrests the effects of malaria. The mosquito-born fever kills 2.7
million people a year, mostly African children. The world spends $300 million a
year on malaria control and a WHO progress report on the $700 million Roll
Back Malaria campaign conducted over the past two years has achieved little. UN
Secretary General Kofi Annan is from Ghana, where successful tests have been
completed, which in hospital trials shows that American Biotech and Clifton
Mining's colloidal silver product ASAP arrests the effects of malaria. The two
companies' representative met this week with WHO executives to discuss the
possible use of ASAP via the World Health Organization. Malaria costs the
African
economy $12 billion a year.
Clifton Mining Company (OTC: CFTN)
Alpine, Utah: November 11th, 2002. Clifton Mining Company (OTC: CFTN) is
pleased to announce that American Biotech Labs, a company in which Clifton owns
approximately 30% has finished the approval process with the U.S. EPA and
expects to get full hospital approval in the next few weeks.
The Testing
In the test work for the EPA hospital approval, the ASAP Solution® had to
kill hundreds of thousands of some of the deadliest types of bacteria found in
the United States within minutes, and it proved able to do so. There were
approximately 1600 individual bacterial tests in just one series alone.
American
Biotech's product was able to pass all the tests.
The Hospital Approval
American Biotech Labs expects to get the full hospital disinfectant approval
within the next 15-45 days. The approval will open the door to sell the highly
effective, yet non-toxic disinfectant to thousands of hospitals, clinics,
rest homes, and other healthcare facilities worldwide. Management expects sales
of the new disinfectant to possibly begin as soon as January 2003. Said Keith
Moeller, V.P., "This will be a very important product for the market. Because
this product is non-toxic and yet highly effective at killing even the MRSA
super bacteria, we expect sales to boom worldwide. Unlike other disinfectants,
this product can be used in and around patients to kill bacteria with no
adverse
effect. It is so safe that it could be sprayed right on the skin or even
consumed orally with no adverse consequences."
Malaria Testing/Drug Approval
A new human trial specifically testing ASAP's effectiveness on malaria is
under way in Ghana, West Africa. In the first two tests, 19 people who had been
diagnosed with malaria were treated with the ASAP Solution. All 19 people
(mostly children) were reported by the doctors as being fully recovered within
just
seven days. The latest malaria tests should be completed within the next 60
days. With no reported failures, the human tests have gone so well that the
official Food and Drug Board of Ghana has already approved the ASAP Solution®
for
drug registration. Recent West African trials also tested the product as a
treatment for fungal skin infections, vaginal infections, urinary tract
infections, tonsillitis, pharingitis, some sexually transmitted diseases,
conjunctivitis, upper respiratory tract infections, nasal and sinus problems,
etc. In
almost every human case tested so far, full recovery was reached in just 1-7
days.
http://www.kitco.com/ind/Chapman/nov122002.html
Michael
